“We are excited to progress Hyalofast toward commercialization in the United States,” said Charles H. Sherwood, Ph.D., Anika’s president and CEO. “We have seen very positive clinical outcomes from Hyalofast in the treatment of knees and ankles internationally, which bodes well as we advance the product in the clinic domestically. As the only HA-based scaffold for regeneration, Hyalofast has distinct advantages over other products constructed of different biomaterials or synthetics. We look forward to commencing our Phase III pivotal trial later this year.”
More articles on orthopedic surgery:
Dr. William Long speaks on computers and robotics as the future of joint replacement surgery
Nashville Business Journal names Dr. Burton Elrod 2015 Health Care Hero
Dr. Brian Mehling delivers keynote address on stem cell therapies at orthopedic research symposium
